Pulmonary Embolism News and Research

RSS

A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung.

Covidien introduces campaign to help educate women about risk of VTE during pregnancy

Covidien, a leading global provider of healthcare products, today announced the launch of its "1 in 1,000" campaign to help educate women about the risk of pregnancy-related blood clots, one of the leading causes of maternal mortality in the developed world.

28 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

A third of ED imaging for PE is avoidable

Data from 12 hospitals in the USA indicate that one-third of imaging performed in the emergency department for suspected pulmonary embolism is avoidable, according to a National Quality Forum measure.

15 Jun 2012

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

ThromboGenics NV and co-development partner BioInvent International announce today the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban, an oral anticoagulant.

5 Jun 2012

Vena cava filter does not improve mortality rates for patients with PE

A filter used to block clots from passing from the veins in the legs to the arteries of the lung does not improve mortality rates for most patients suffering a pulmonary embolism. However, if a patient is unstable - in shock or requires a ventilator - filters can save lives.

1 Jun 2012

Alteplase can benefit stroke patients aged over 80 years according to new studies

The Lancet today publishes two papers Online First about the use of alteplase in stroke, timed to coincide with their presentation at the European Stroke Conference in Lisbon, Portugal.

23 May 2012

$Children with pelvic and thigh fractures rarely develop dangerous blood clots$

Children with pelvic and thigh fractures rarely develop dangerous blood clots

Children with pelvic and thigh fractures develop dangerous blood clots so rarely that anti-clotting therapy should be given only to those with underlying conditions that increase clotting risk, according to a study from Johns Hopkins Children's Center.

21 May 2012

$Anti-clotting drugs rarely needed in children with big-bone fractures$

Anti-clotting drugs rarely needed in children with big-bone fractures

21 May 2012

FDA decides to strengthen warning labels on oral contraceptive YAZ, Yasmin

The Federal Drug Administration (FDA) has recently decided to strengthen warning labels on the oral contraceptive YAZ and its sister drug Yasmin regarding increased risks of blood clots from using the medications.

17 May 2012

BiO2 Medical receives CE Mark approval for Angel Catheter to prevent PE

BiO2 Medical, Inc. a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, announced today that it has received CE Mark approval for the Angel Catheter, a Nitinol Inferior Vena Cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing Pulmonary Embolism (PE) in critically ill patients.

16 May 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

Rutin may inhibit formation of blood clots

A compound called rutin, commonly found in fruits and vegetables and sold over the counter as a dietary supplement, has been shown to inhibit the formation of blood clots in an animal model of thrombosis.

9 May 2012

EKOS launches two landmark clinical studies on pulmonary embolism

EKOS Corporation today announced the launch of two more landmark clinical studies named SEATTLE I & II, intended to further establish the safety and efficacy of its unique, ultrasound-accelerated thrombolysis in treating patients with life-threatening pulmonary embolism.

3 May 2012

Orthopaedic research studies in the Journal of Bone and Joint Surgery

Below are highlights of orthopaedic research studies appearing in the April 18th issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issue's full Table of Contents.

21 Apr 2012

Timing pregnancy an important health concern for women

A newly published article in the journal Nursing for Women’s Health highlights the importance of a woman’s ability to time her childbearing. The author asserts that contraception is a means of health promotion and women who work with their health care providers to ensure they are healthy prior to conceiving can minimize their risk of complications during pregnancy and childbirth.

11 Apr 2012

ACR finds list of five medical imaging exams

As part of its ongoing efforts to ensure safe, effective and appropriate use of medical imaging, the American College of Radiology (ACR) identified a list of five imaging exams whose necessity should be discussed before being ordered.

5 Apr 2012

Lower dose of thrombolytics can treat moderate pulmonary embolism

Pulmonary embolism -- the sudden blockage of an artery in the lung -- is estimated to cause over 100,000 deaths each year in the U.S. Although thrombolytics, or "clot-buster" drugs, are currently reserved to treat only the most severe cases of pulmonary embolism, new data suggest that when used at lower doses, these drugs are also safe and effective for more common, moderate cases of pulmonary embolism, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

28 Mar 2012

Rivaroxaban found safe and effective in pulmonary embolism

Rivaroxaban has been found to be effective in the prevention of venous thromboembolism (VTE) after orthopedic surgery, for the prevention of stroke in AF (Atrial fibrillation) patients, and as additional therapy to conventional antiplatelet therapy in ACS (Acute coronary syndrome) patients.

27 Mar 2012

Rivaroxaban safer, effective than standard therapy in treating PE

A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism - a blockage of lung blood vessels usually caused by a clot - and showed comparable efficacy, according to data from the EINSTEIN-PE trial presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

BiO2 Medical completes $13.7M Series B round of funding

BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has recently completed its $13.7M Series B round of funding, which included the conversion of a $1M State of Texas Emerging Technology Fund (ETF) award.

26 Mar 2012